BG
ECYT

BlackRock Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

BlackRock Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,776
Closed -$17K – 3062
2015
Q3 		$17K Buy
+3,776
New +$19.8K ﹤0.01% 2997

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Group's ECYT Position: Q4 2015 in Review

BlackRock Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2015, closing a stake of 3,776 shares — an estimated $17K sold.

BlackRock Group first reported a position in ECYT in Q3 2015 and held it in 1 quarter. The position peaked at $17K in Q3 2015. 102 funds tracked by Wall St. Rank hold ECYT as of Q4 2015.

  • BlackRock Group reported no remaining Endocyte, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • BlackRock Group sold 3,776 Endocyte, Inc. Common Stock shares in Q4 2015, an estimated $17K.
  • BlackRock Group first reported a position in Endocyte, Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • BlackRock Group's Endocyte, Inc. Common Stock position peaked at $17K in Q3 2015.
  • 102 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2015.

Based on BlackRock Group's 13F filing for Q4 2015, filed 11 Feb 2016.